Format

Send to

Choose Destination
Int J Mol Sci. 2016 Mar 22;17(3):415. doi: 10.3390/ijms17030415.

Ocular Stem Cell Research from Basic Science to Clinical Application: A Report from Zhongshan Ophthalmic Center Ocular Stem Cell Symposium.

Author information

1
State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou 510060, China. ouyhong3@mail.sysu.edu.cn.
2
Department of Ophthalmology, Stanford University, Palo Alto, CA 94303, USA. Jeffrey.Goldberg@Stanford.edu.
3
State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou 510060, China. chenshy23@mail.sysu.edu.cn.
4
Unit on Retinal Neurophysiology, National Eye Institute, National Institutes of Health, Bethesda, MD 20892, USA. liwei2@nei.nih.gov.
5
Department of Ophthalmology, Tongji University, Shanghai 200092, China. gtxu@tongji.edu.cn.
6
Department of Ophthalmology, Xiamen University, Xiamen 361005, China. wei1018@xmu.edu.cn.
7
Department of Ophthalmology, University of California San Diego, San Diego, CA 92093, USA. k5zhang@ad.ucsd.edu.
8
Laboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, MD 20892, USA. nussenblattr@nei.nih.gov.
9
State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou 510060, China. yzliu62@yahoo.com.
10
Stowers Institute for Medical Research, Kansas City, MO 64110, USA. tgx@stowers.org.
11
State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou 510060, China. chanc@nei.nih.gov.
12
Laboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, MD 20892, USA. chanc@nei.nih.gov.
13
Wilmer Ophthalmological Institute, Johns Hopkins University, Baltimore, MD 21231, USA. dzack@jhmi.edu.

Abstract

Stem cells hold promise for treating a wide variety of diseases, including degenerative disorders of the eye. The eye is an ideal organ for stem cell therapy because of its relative immunological privilege, surgical accessibility, and its being a self-contained system. The eye also has many potential target diseases amenable to stem cell-based treatment, such as corneal limbal stem cell deficiency, glaucoma, age-related macular degeneration (AMD), and retinitis pigmentosa (RP). Among them, AMD and glaucoma are the two most common diseases, affecting over 200 million people worldwide. Recent results on the clinical trial of retinal pigment epithelial (RPE) cells from human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) in treating dry AMD and Stargardt's disease in the US, Japan, England, and China have generated great excitement and hope. This marks the beginning of the ocular stem cell therapy era. The recent Zhongshan Ophthalmic Center Ocular Stem Cell Symposium discussed the potential applications of various stem cell types in stem cell-based therapies, drug discoveries and tissue engineering for treating ocular diseases.

KEYWORDS:

age-related macular degeneration; eye diseases; glaucoma; limbal stem cell deficiency; regenerative medicine; stem cells

PMID:
27102165
PMCID:
PMC4813266
DOI:
10.3390/ijms17030415
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Multidisciplinary Digital Publishing Institute (MDPI) Icon for PubMed Central
Loading ...
Support Center